National Medical Device Catalog:What is the National Medical Device Catalog and what is its purpose?
Q: What is the National Medical Device Catalog and what is its purpose?
A: The National Medical Device Catalog is an official registry maintained by China's National Medical Products Administration (NMPA) that classifies and lists all medical devices legally permitted for use in the country. Its primary purpose is to standardize the naming, classification, and management of medical devices, ensuring traceability and regulatory oversight. According to the NMPA's 2026 Medical Device Regulatory Annual Report, the catalog is updated periodically to reflect technological advancements and emerging clinical needs. It serves as a foundational reference for manufacturers, importers, healthcare providers, and regulators, helping to streamline market access, post-market surveillance, and adverse event reporting. By providing a unified nomenclature, the catalog reduces ambiguity in device identification, facilitates international harmonization, and supports the implementation of unique device identification (UDI) systems. In 2026, the NMPA emphasized that compliance with the catalog is mandatory for all devices marketed in China, reinforcing its role as a cornerstone of medical device governance.
Q: How are medical devices classified under the National Medical Device Catalog in 2026?
A: Under the National Medical Device Catalog, devices are classified into three classes based on risk level: Class I (low risk), Class II (moderate risk), and Class III (high risk). This classification follows the NMPA's 2026 Updated Rules for Medical Device Classification, which align with international practices. Class I devices typically include simple instruments like tongue depressors, while Class III covers implantable devices such as heart valves. The catalog specifies the classification criteria, examples, and applicable regulatory pathways for each category. In 2026, the NMPA introduced refined subclassifications for emerging technologies like AI-based diagnostic software and biodegradable implants, as noted in the 2026 Medical Device Classification Guidance. Manufacturers must self-identify the class of their device using the catalog; misclassification can lead to regulatory penalties. The classification determines the level of pre-market review, clinical trial requirements, and post-market obligations, ensuring that regulatory scrutiny is proportionate to potential harm.
Q: What updates were made to the National Medical Device Catalog in 2026?
A: In 2026, the NMPA released significant updates to the National Medical Device Catalog, as detailed in the 2026 Medical Device Catalog Revision Announcement. Key changes include the addition of 152 new device categories, primarily in digital health, personalized medicine, and minimally invasive surgical tools. For instance, AI-driven software for early cancer detection and 3D-printed orthopedic implants were formally incorporated. The revision also reclassified 45 existing devices to reflect new risk assessments, such as moving certain wearable cardiac monitors from Class II to Class III due to increased diagnostic reliance. Furthermore, the 2026 catalog streamlined naming conventions to reduce redundancies and enhance interoperability with the UDI database. The NMPA emphasized that these updates aim to keep pace with innovation while safeguarding public health. Stakeholders were given a six-month transition period to comply with the revised catalog, which took effect on July 1, 2026. This proactive approach underscores China's commitment to adaptive regulation.
Q: How does the National Medical Device Catalog impact market access for medical devices in China?
A: The National Medical Device Catalog directly impacts market access by determining the regulatory pathway for each device. To enter the Chinese market, a device must be listed in the catalog and classified accordingly. According to the NMPA's 2026 Market Access Guide, Class I devices require only filing, while Class II and III devices need registration with increasing levels of clinical evidence. The catalog also dictates whether a device can benefit from expedited review programs, such as the Innovation Channel for breakthrough technologies. In 2026, the NMPA reported that over 90% of registration applications referenced the catalog for classification, highlighting its centrality. Non-compliance can result in rejection or delays. Moreover, the catalog aligns with international standards, facilitating foreign manufacturers' entry. However, it also imposes strict labeling and UDI requirements. Overall, the catalog serves as both a gatekeeper and a roadmap, ensuring that only safe and effective devices reach patients while fostering a predictable regulatory environment.
Dialogue about
Common scenarios of "National Medical Device Catalog"
【Regulatory Affairs Manager】 Good morning, everyone. Today we need to finalize the submission for the National Medical Device Catalog. Our new AI-powered diagnostic imaging system is ready, and we must ensure it meets all criteria.
【Clinical Expert】 I've reviewed the clinical trial data. The system shows high sensitivity and specificity for early detection. But we need to confirm if it falls under Class III or Class IIb according to the catalog's classification rules.
【Regulatory Affairs Manager】 Exactly. The catalog has specific categories for AI-based devices. Let's check the latest version. According to the 2024 National Medical Device Catalog, AI diagnostic software is classified under 'Computer-Assisted Diagnostic Software' with a risk level of III if it provides independent diagnostic recommendations.
【Quality Assurance Specialist】 Does that mean we need to submit additional clinical evidence? The catalog requires a comprehensive clinical evaluation report for Class III devices, including post-market surveillance plans.
【Clinical Expert】 Yes, and we also need to demonstrate that the algorithm is explainable and that the training data is representative. The catalog emphasizes transparency and bias mitigation for AI devices.
【Regulatory Affairs Manager】 We have that covered. Our team has prepared a detailed algorithm description and a bias analysis report. Now, regarding the submission process, the catalog specifies that we must file through the National Medical Products Administration's online portal with a dossier including technical documentation, risk analysis, and clinical evaluation.
【Quality Assurance Specialist】 I've checked the dossier checklist. We are missing the software validation and verification report. That's a mandatory item under the catalog's 'Software as a Medical Device' section.
【Clinical Expert】 I can work with the engineering team to complete that. But we also need to ensure the device's intended use aligns with the catalog's scope. Our system is for lung nodule detection, which is explicitly listed.
【Regulatory Affairs Manager】 Great. Another point: the catalog has a separate category for 'AI-assisted treatment planning' if the device goes beyond diagnosis. Ours is purely diagnostic, so we stay in the diagnostic category.
【Quality Assurance Specialist】 What about the labeling requirements? The catalog mandates that the label must include the catalog number, risk class, and a clear statement that the device is AI-based and requires human oversight.
【Clinical Expert】 We've incorporated that into the user manual and the on-screen warnings. Also, the catalog requires a unique device identification (UDI) that includes the catalog code.
【Regulatory Affairs Manager】 I'll ensure the UDI is assigned correctly. Now, let's discuss timelines. The catalog's submission window for new devices is open until the end of next quarter. We should aim to submit at least a month early to address any queries.
【Quality Assurance Specialist】 Agreed. I'll coordinate with the software team to get the validation report by next week. We also need to update our quality management system to reflect the catalog requirements.
【Clinical Expert】 One more thing: the catalog has provisions for 'predicate devices' if we can demonstrate substantial equivalence. But since our AI is novel, we might not have a predicate. We should prepare for a de novo classification.
【Regulatory Affairs Manager】 That's a valid point. The catalog allows for de novo requests. We'll need to provide a detailed justification for a new category. I'll draft that section.
【Quality Assurance Specialist】 Also, the catalog requires a post-market clinical follow-up plan for AI devices to monitor performance drift. We need to outline how we'll collect real-world data and update the algorithm accordingly.
【Clinical Expert】 I'll design a post-market surveillance protocol that includes periodic re-training and performance audits. The catalog emphasizes continuous learning for AI devices.
【Regulatory Affairs Manager】 Excellent. Let's summarize: we need the software validation report, UDI assignment, de novo justification, and post-market plan. I'll compile the dossier and schedule a pre-submission meeting with the NMPA to clarify any ambiguities.
【Quality Assurance Specialist】 I'll also verify that our cybersecurity measures meet the catalog's requirements for AI devices, which include encryption and access controls.
【Clinical Expert】 And I'll ensure the clinical evaluation report includes subgroup analyses to demonstrate effectiveness across diverse populations, as the catalog stresses health equity.
